A detailed history of Axa S.A. transactions in Argenx Se stock. As of the latest transaction made, Axa S.A. holds 33,574 shares of ARGX stock, worth $18.9 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
33,574
Previous 36,372 7.69%
Holding current value
$18.9 Million
Previous $15.6 Million 16.41%
% of portfolio
0.06%
Previous 0.05%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $1.21 Million - $1.54 Million
-2,798 Reduced 7.69%
33,574 $18.2 Million
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $7,120 - $9,031
20 Added 0.06%
36,372 $15.6 Million
Q1 2024

May 15, 2024

SELL
$356.95 - $413.29 $2.4 Million - $2.78 Million
-6,721 Reduced 15.6%
36,352 $14.3 Million
Q4 2023

Jul 16, 2024

BUY
$338.91 - $506.01 $2.28 Million - $3.4 Million
6,721 Added 18.49%
43,073 $16.4 Million
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $416,181 - $621,380
-1,228 Reduced 2.77%
43,073 $16.4 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $9.82 Million - $14.6 Million
26,582 Added 150.02%
44,301 $21.8 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $87,514 - $102,686
243 Added 1.39%
17,719 $6.91 Million
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $15.6 Million - $18.9 Million
-46,708 Reduced 72.77%
17,476 $6.51 Million
Q4 2022

Feb 14, 2023

SELL
$342.17 - $402.31 $73,224 - $86,094
-214 Reduced 0.33%
64,184 $24.3 Million
Q3 2022

Feb 14, 2023

SELL
$343.2 - $395.75 $6.2 Million - $7.15 Million
-18,079 Reduced 21.92%
64,398 $22.7 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $6.2 Million - $7.15 Million
-18,079 Reduced 21.92%
64,398 $22.7 Million
Q2 2022

Feb 14, 2023

SELL
$269.58 - $378.88 $1.75 Million - $2.46 Million
-6,506 Reduced 7.31%
82,477 $31.2 Million
Q2 2022

Aug 15, 2022

SELL
$269.58 - $378.88 $1.75 Million - $2.46 Million
-6,506 Reduced 7.31%
82,477 $31.2 Million
Q1 2022

Feb 14, 2023

BUY
$254.45 - $351.06 $6.26 Million - $8.63 Million
24,585 Added 38.18%
88,983 $28.1 Million
Q1 2022

May 13, 2022

SELL
$254.45 - $351.06 $166,919 - $230,295
-656 Reduced 0.73%
88,983 $28.1 Million
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $13.4 Million - $17.4 Million
49,401 Added 122.77%
89,639 $31.4 Million
Q3 2021

Nov 15, 2021

BUY
$295.0 - $350.58 $436,895 - $519,208
1,481 Added 3.82%
40,238 $12.2 Million
Q2 2021

Aug 13, 2021

SELL
$257.11 - $319.92 $756,931 - $941,844
-2,944 Reduced 7.06%
38,757 $11.7 Million
Q1 2021

May 14, 2021

SELL
$268.3 - $380.31 $995,929 - $1.41 Million
-3,712 Reduced 8.17%
41,701 $11.5 Million
Q4 2020

Feb 12, 2021

BUY
$248.13 - $308.36 $454,326 - $564,607
1,831 Added 4.2%
45,413 $13.4 Million
Q3 2020

Nov 13, 2020

SELL
$215.51 - $272.51 $88,574 - $112,001
-411 Reduced 0.93%
43,582 $11.4 Million
Q2 2020

Aug 14, 2020

SELL
$127.44 - $232.72 $327,011 - $597,159
-2,566 Reduced 5.51%
43,993 $9.91 Million
Q1 2020

May 15, 2020

SELL
$108.83 - $165.23 $1.36 Million - $2.07 Million
-12,525 Reduced 21.2%
46,559 $6.13 Million
Q4 2019

Feb 18, 2020

SELL
$106.59 - $164.21 $2.23 Million - $3.43 Million
-20,880 Reduced 26.11%
59,084 $9.48 Million
Q3 2019

Nov 14, 2019

SELL
$113.31 - $150.51 $13,483 - $17,910
-119 Reduced 0.15%
79,964 $9.11 Million
Q2 2019

Aug 13, 2019

SELL
$115.0 - $141.58 $3.2 Million - $3.94 Million
-27,823 Reduced 25.78%
80,083 $11.3 Million
Q2 2018

Aug 13, 2018

SELL
$74.84 - $100.16 $2.85 Million - $3.82 Million
-38,112 Reduced 26.1%
107,906 $8.94 Million
Q1 2018

May 14, 2018

SELL
$56.95 - $85.19 $1.66 Million - $2.49 Million
-29,227 Reduced 16.68%
146,018 $11.7 Million
Q4 2017

Feb 13, 2018

BUY
$22.57 - $63.56 $567,161 - $1.6 Million
25,129 Added 16.74%
175,245 $11.1 Million
Q3 2017

Nov 13, 2017

BUY
$19.81 - $22.61 $2.97 Million - $3.39 Million
150,116
150,116 $3.39 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.